The Ivy Brain Tumor Center at Barrow Neurological Institute announced that patient recruitment has opened for a Phase 0 clinical trial to evaluate two targeted therapy drugs, abemaciclib and LY3214996. The study will evaluate central nervous system (CNS) penetration in patients with recurrent glioblastoma scheduled for resection. This is the first time a combination of these two drugs will be tested in brain tumor patients.
“It’s very important to me that the medical personnel in this state have the right tools and supplies to fight this battle,” said Catherine Ivy, co-founder of the Ivy Brain Tumor Center.
Barrow Neurological Institute neurosurgeon, Dr. Zaman Mirzadeh has received a three-year, $1.8 million grant from the U.S. Department of Defense (DoD) to study the rewiring of the brain to normalize blood sugar levels in diabetes. As a member of the Ivy Center team, Dr. Mirzadeh runs a lab focused on identifying unique metabolic pathways co-opted by glioblastoma to drive tumor growth.
The Ivy Brain Tumor Center at the Barrow Neurological Institute is a nonprofit center conducting early phase clinical trials of new therapeutics for brain tumors. In this interview with Oncology Times, Dr. Nader Sanai explains how the phase 0 trials work and why the center is so excited about them.
The Ivy Brain Tumor Center at Barrow Neurological Institute has announced a partnership with two East Valley hospitals to expand its novel Phase 0 clinical trials program, the first of its kind in neuro-oncology.
Catherine Ivy, who lost her husband a decade ago to a devastating and sudden brain cancer, shares her personal journey of grief and purpose, which led to the founding of the Ivy Brain Tumor Center at the Barrow Neurological Institute.
Brain cancer survivor Lanette Veres sends cards and packages to others with the disease. She believes no one should face cancer alone.
In this edition of The Onco’Zine Brief, Peter Hofland talks with Catherine Ivy about how after losing her husband Ben to glioblastoma she became a tireless advocate for brain cancer patients.
The Ivy Brain Tumor Center at the Barrow Neurological Institute and SonALASense have signed an strategic agreement to jointly test a new and non-invasive drug-device combination, called sonodynamic therapy or SDT, for the treatment of recurrent glioblastoma.
The Ivy Brain Tumor Center at the Barrow Neurological Institute, today announced a strategic collaboration with SonALASense to develop and test a new, non-invasive drug-device combination, sonodynamic therapy (SDT), for recurrent glioblastoma through a Phase 0/2 clinical trial.